Pediatric HAE Study Supports Safety and Early Relief With Sebetralstat Sebetralstat provides comparable drug exposure and early symptom relief in children aged 2 to 11 years with HAE as that seen in older patients.

#ACAAI25: #Sebetralstat appears to be a safe, effective, and easy-to-use oral treatment for acute #HAE attacks in children aged 2 to 11 years, with drug exposure and early symptom relief comparable with older patients.

Read more: https://bit.ly/4oyKrOL

#RareDisease #KONFIDENTKID #MedSky